Sen. John Boozman Sells Off Shares of Boston Scientific Corporation (NYSE:BSX)

Senator John Boozman (R-Arkansas) recently sold shares of Boston Scientific Corporation (NYSE:BSX). In a filing disclosed on January 13th, the Senator disclosed that they had sold between $1,001 and $15,000 in Boston Scientific stock on December 17th.

Senator John Boozman also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Super Micro Computer (NASDAQ:SMCI) on 12/31/2025.
• Purchased $1,001 – $15,000 in shares of iShares S&P 500 Growth ETF (NYSEARCA:IVW) on 12/31/2025.
• Purchased $1,001 – $15,000 in shares of iShares Core S&P Small-Cap ETF (NYSEARCA:IJR) on 12/26/2025.
• Sold $1,001 – $15,000 in shares of SPDR S&P Regional Banking ETF (NYSEARCA:KRE) on 12/26/2025.
• Purchased $15,001 – $50,000 in shares of Tradr 2X Long SPY Monthly ETF (NASDAQ:SPYM) on 12/24/2025.
• Sold $1,001 – $15,000 in shares of abrdn Physical Palladium Shares ETF (NYSEARCA:PALL) on 12/24/2025.
• Sold $1,001 – $15,000 in shares of abrdn Physical Platinum Shares ETF (NYSEARCA:PPLT) on 12/24/2025.
• Sold $1,001 – $15,000 in shares of iShares Silver Trust (NYSEARCA:SLV) on 12/24/2025.
• Purchased $1,001 – $15,000 in shares of Wells Fargo & Company (NYSE:WFC) on 12/17/2025.
• Purchased $1,001 – $15,000 in shares of Microsoft (NASDAQ:MSFT) on 12/17/2025.

Boston Scientific Price Performance

BSX stock opened at $90.00 on Friday. The business has a 50 day simple moving average of $97.14 and a 200-day simple moving average of $100.46. The company has a market capitalization of $133.41 billion, a P/E ratio of 48.13, a PEG ratio of 1.66 and a beta of 0.67. Boston Scientific Corporation has a twelve month low of $85.98 and a twelve month high of $109.50. The company has a current ratio of 1.51, a quick ratio of 0.96 and a debt-to-equity ratio of 0.47.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, beating the consensus estimate of $0.71 by $0.04. Boston Scientific had a net margin of 14.43% and a return on equity of 19.46%. The firm had revenue of $5.07 billion during the quarter, compared to the consensus estimate of $4.97 billion. During the same quarter in the prior year, the firm earned $0.63 EPS. Boston Scientific’s revenue for the quarter was up 20.3% on a year-over-year basis. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. As a group, equities analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current year.

Insiders Place Their Bets

In other Boston Scientific news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the company’s stock in a transaction on Monday, November 3rd. The stock was sold at an average price of $99.47, for a total value of $4,973,500.00. Following the sale, the executive vice president owned 178,342 shares of the company’s stock, valued at approximately $17,739,678.74. This represents a 21.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Ellen M. Zane sold 12,891 shares of Boston Scientific stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $98.28, for a total value of $1,266,927.48. Following the transaction, the director directly owned 24,134 shares of the company’s stock, valued at $2,371,889.52. This trade represents a 34.82% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 93,095 shares of company stock worth $9,305,450. 0.50% of the stock is owned by corporate insiders.

More Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Strategic rationale — the acquisition gives BSX immediate scale in mechanical thrombectomy and neurovascular devices, expanding its cardiovascular portfolio and entry into fast‑growing vascular segments, which could drive medium‑term revenue and market-share gains. Boston Scientific announces agreement to acquire Penumbra, Inc.
• Neutral Sentiment: Complementary M&A and product wins — recent smaller deals (Valencia Technologies) and regulatory wins (Farapoint PFA catheter, CE mark for coils) continue to diversify growth engines but are incremental compared with the Penumbra transaction. Boston Scientific to buy incontinence device maker Valencia
• Neutral Sentiment: Analyst views supportive — some analysts reiterated buy ratings and highlighted long‑term upside from the company’s EP and electro‑physiology franchise, partially offsetting integration concerns. Farapoint PFA Approval Strengthens EP Ecosystem and Supports Buy Rating
• Negative Sentiment: Market reaction and financing concerns — investors sold BSX as the deal is large (~$14.5B enterprise value), raising near‑term concerns about dilution, integration costs and leverage; Penumbra shares rose sharply while BSX declined on the news. Boston Scientific to acquire Penumbra in $14.5B deal
• Negative Sentiment: Bearish options flow — unusually large put buying (≈35,600 puts, ~161% above typical daily volume) signals elevated short‑term investor hedging or bearish speculation, adding downward pressure.
• Negative Sentiment: Regulatory / litigation flags for target — shareholder‑investigation notices related to Penumbra were circulated, which could add legal/transaction risk or distract management during integration. BRODSKY & SMITH SHAREHOLDER UPDATE

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of BSX. Vanguard Group Inc. lifted its stake in shares of Boston Scientific by 0.8% in the third quarter. Vanguard Group Inc. now owns 138,249,447 shares of the medical equipment provider’s stock valued at $13,497,294,000 after purchasing an additional 1,115,337 shares during the period. State Street Corp boosted its stake in shares of Boston Scientific by 1.1% during the 2nd quarter. State Street Corp now owns 65,191,864 shares of the medical equipment provider’s stock worth $7,002,258,000 after acquiring an additional 713,379 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Boston Scientific by 2.0% in the 2nd quarter. Geode Capital Management LLC now owns 32,424,982 shares of the medical equipment provider’s stock worth $3,466,320,000 after acquiring an additional 622,602 shares during the period. Norges Bank purchased a new position in Boston Scientific in the 2nd quarter valued at approximately $2,089,937,000. Finally, Invesco Ltd. raised its holdings in Boston Scientific by 0.7% during the third quarter. Invesco Ltd. now owns 16,963,344 shares of the medical equipment provider’s stock worth $1,656,131,000 after purchasing an additional 111,826 shares during the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Analyst Upgrades and Downgrades

BSX has been the topic of a number of research reports. Erste Group Bank lowered Boston Scientific from a “buy” rating to a “hold” rating in a report on Friday, October 3rd. Truist Financial lowered their target price on Boston Scientific from $130.00 to $120.00 and set a “buy” rating on the stock in a research note on Thursday, December 18th. Leerink Partners upped their price target on Boston Scientific from $127.00 to $128.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 1st. Needham & Company LLC reaffirmed a “buy” rating on shares of Boston Scientific in a report on Thursday. Finally, Barclays boosted their price objective on shares of Boston Scientific from $133.00 to $136.00 and gave the company an “overweight” rating in a research note on Thursday, October 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $125.21.

About Senator Boozman

John Boozman (Republican Party) is a member of the U.S. Senate from Arkansas. He assumed office on January 3, 2011. His current term ends on January 3, 2029. Boozman (Republican Party) ran for re-election to the U.S. Senate to represent Arkansas. He won in the general election on November 8, 2022. Boozman won re-election in 2016. He faced Democrat Conner Eldridge, Libertarian Frank Gilbert, and write-in candidate Jason Tate in the general election. Arkansas’ U.S. Senate race was rated as safely Republican in 2016. Boozman began his political career in the U.S. House. He won a special election in 2001 and served in that position until his election to the Senate in 2010. Prior to his political career, Boozman worked as an optometrist. As of a 2014 analysis of multiple outside rankings, Boozman is an average Republican member of Congress, meaning he will vote with the Republican Party on the majority of bills. Below is an abbreviated outline of Boozman’s academic, professional, and political career: 2011-Present: U.S. Senator from Arkansas 2001-2011: U.S. Representative from Arkansas 1977: Graduated from Southern College of Optometry

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.